Spots Global Cancer Trial Database for recurrent glioblastoma
Every month we try and update this database with for recurrent glioblastoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma | NCT00715013 | Recurrent Gliob... | Patupilone | 18 Years - 80 Years | University of Zurich | |
| A Study to Evaluate the Safety, Tolerance and Initial Efficacy of EGFRvIII CAR-T on Glioblastoma | NCT05802693 | Recurrent Gliob... | Targeted Epider... | 18 Years - 70 Years | Beijing Tsinghua Chang Gung Hospital | |
| Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma | NCT04201873 | Recurrent Gliob... | Dendritic Cell ... Pembrolizumab Placebo Adminis... Poly ICLC | 18 Years - | Jonsson Comprehensive Cancer Center | |
| A Panobinostat Presurgery | NCT01115036 | Recurrent Gliob... | panobinostat | 18 Years - | Duke University | |
| Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults | NCT04323046 | Glioblastoma Malignant Gliom... Recurrent Gliob... Recurrent Malig... Recurrent Grade... Grade III Gliom... | Nivolumab Quality-of-Life... Questionnaire A... | 6 Months - 25 Years | University of California, San Francisco | |
| Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients | NCT04988750 | Recurrent Gliob... | NaviFUS System | 20 Years - | NaviFUS Corporation | |
| Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | NCT01814813 | Recurrent Gliob... Recurrent Adult... Gliosarcoma | HSPPC-96 bevacizumab | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma | NCT05284643 | Recurrent Gliob... | Intensity Modul... Bevacizumab | 18 Years - | University of Miami | |
| A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma | NCT06097975 | Recurrent Gliob... | Neo-adjuvant ni... Neurosurgery an... Adjuvant nivolu... | 18 Years - | Universitair Ziekenhuis Brussel | |
| FMISO PET Study of Glioblastoma | NCT02076152 | Recurrent Gliob... | FMISO PET MRI Bevacizumab CCNU | 18 Years - | Massachusetts General Hospital | |
| Repurposed Drugs in Research for Cancer Clinical Trials- Pitavastatin | NCT05977738 | Glioblastoma Mu... Recurrent Gliob... | Pitavastatin ca... | 18 Years - | Erasmus Medical Center | |
| Retifanlimab With Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma | NCT06160206 | Recurrent Gliob... Recurrent WHO G... | Bevacizumab Biospecimen Col... Computed Tomogr... Electronic Heal... Hypofractionate... Magnetic Resona... Retifanlimab | 18 Years - | Academic and Community Cancer Research United | |
| Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma | NCT02858895 | Glioblastoma Grade IV Astroc... Glioblastoma Mu... Grade IV Glioma | MDNA55 | 18 Years - | Medicenna Therapeutics, Inc. | |
| Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma | NCT06344130 | Astrocytoma Glioma Recurrent Gliob... | Radiation Thera... | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors | NCT04541225 | Glioma Glioma, Maligna... Glioma, Mixed Glial Cell Tumo... Breast Cancer Breast Carcinom... Cancer of Breas... Cancer of the B... Breast Tumor Malignant Tumor... Advanced Breast... Advanced Breast... Metastatic Brea... Metastatic Brea... Prostate Cancer Prostatic Cance... Cancer of Prost... Cancer of the P... Prostate Neopla... Castrate Resist... Castration-resi... Castration Resi... Glioblastoma Recurrent Gliob... | NUV-422 | 18 Years - | Nuvation Bio Inc. | |
| Reirradiation and Niraparib in Patients With Recurrent Glioblastoma | NCT05666349 | Recurrent Gliob... | Niraparib Re-irradiation ... | 18 Years - | University College, London | |
| Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields | NCT04469075 | Glioblastoma Recurrent Gliob... Skin Toxicity | Clindamycin Pho... Triamcinolone A... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Feasibility of Individualized Therapy for Recurrent Glioblastoma | NCT03681028 | Recurrent Gliob... | Individualized ... | 18 Years - | University of California, San Francisco | |
| Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma | NCT01582152 | Brain Neoplasms Central Nervous... | TPI287 Bevacizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer | NCT03107780 | Glioblastoma Gliosarcoma MGMT-Unmethylat... Recurrent Gliob... | Biospecimen Col... Magnetic Resona... Navtemadlin Radiation Thera... | 18 Years - | National Cancer Institute (NCI) | |
| Tryptophan Metabolism in Human Brain Tumors | NCT02367482 | Glioblastoma | 22 Years - | Wayne State University | ||
| Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma | NCT01266031 | Malignant Gliom... Recurrent Gliob... | vorinostat bevacizumab | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Anti-Lag-3 (Relatlinib) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma | NCT06325683 | Recurrent Gliob... | Biopsy Biospecimen Col... Lomustine Magnetic Resona... Nivolumab Relatlimab Surgical Proced... | 18 Years - | National Cancer Institute (NCI) | |
| Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas | NCT00586508 | Recurrent Gliob... | enzastaurin bevacizumab Enzyme-inducing... Non-enzyme indu... | 18 Years - | Eli Lilly and Company | |
| IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM | NCT04003649 | Recurrent Gliob... Refractory Glio... | IL13Ralpha2-spe... Ipilimumab Nivolumab Quality-of-Life... Questionnaire A... | 18 Years - | City of Hope Medical Center | |
| Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma | NCT06090903 | Glioblastoma Recurrent Gliob... Resectable Glio... | Biospecimen Col... Magnetic Resona... Medical Chart R... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients | NCT05108012 | Glioblastoma Mu... Recurrent Gliob... | NK cell therapy | 3 Years - 60 Years | Royan Institute | |
| A Phase III Study of Re-Irradiation in Recurrent Glioblastoma | NCT01830101 | Recurrent Gliob... | TMZ plus concur... Temozolomide | 18 Years - | AHS Cancer Control Alberta | |
| Safety of IMRT Treatment With Inhomogeneous Dose in Patients With Relapsed High-grade Gliomas. | NCT04610229 | Glioblastoma Mu... Glioblastoma Glioblastoma, A... | Hypofractionati... | 18 Years - | Arcispedale Santa Maria Nuova-IRCCS | |
| Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma | NCT02010606 | Glioblastoma Glioblastoma Mu... Glioma Astrocytoma Brain Tumor | Dendritic cell ... Dendritic cell ... | 18 Years - | Cedars-Sinai Medical Center | |
| Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma | NCT05017610 | Recurrent Gliob... Recurrent Glios... | Liothyronine Lomustine Methimazole | 18 Years - | Emory University | |
| Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT | NCT04763031 | Glioblastoma GBM Recurrent GBM | Intra-operative... | 18 Years - | Parkridge Medical Center | |
| Natural Progesterone for the Treatment of Recurrent Glioblastoma | NCT05091866 | Gliosarcoma Recurrent Gliob... | Quality-of-Life... Questionnaire A... Therapeutic Pro... | 18 Years - | Emory University | |
| Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | NCT01814813 | Recurrent Gliob... Recurrent Adult... Gliosarcoma | HSPPC-96 bevacizumab | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas | NCT00586508 | Recurrent Gliob... | enzastaurin bevacizumab Enzyme-inducing... Non-enzyme indu... | 18 Years - | Eli Lilly and Company | |
| Combination of Stereotactic Radiosurgery and Enhanced Immunotherapy for Recurrent Glioblastomas(inSituVac2)(CSREIG) | NCT05131711 | Recurrent Gliob... | Combined stereo... | 18 Years - 65 Years | Beijing Tiantan Hospital | |
| VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma | NCT03750071 | Recurrent Gliob... | VXM01 Avelumab | 18 Years - | Vaximm GmbH | |
| Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma | NCT05201326 | Recurrent Gliob... | Bevacizumab，Iri... | 18 Years - 75 Years | Ruijin Hospital | |
| Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma | NCT02010606 | Glioblastoma Glioblastoma Mu... Glioma Astrocytoma Brain Tumor | Dendritic cell ... Dendritic cell ... | 18 Years - | Cedars-Sinai Medical Center | |
| The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma | NCT06220552 | Recurrent Gliob... | Sintilimab Low-dose Radiot... | 18 Years - | Fifth Affiliated Hospital, Sun Yat-Sen University | |
| A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | NCT04478279 | Glioblastoma Melanoma Stage ... Breast Cancer Prostate Cancer Glioblastoma Mu... GBM Brain Cancer Metastatic Brea... Metastatic Mela... Metastatic Pros... Melanoma Recurr... Prostate Cancer... Recurrent Gliob... Newly Diagnosed... | ST101 Temozolomide Radiation | 18 Years - | Sapience Therapeutics | |
| Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas | NCT02343406 | Glioblastoma | Depatuxizumab m... Temozolomide Lomustine | - 99 Years | AbbVie | |
| Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma | NCT05879120 | Recurrent Gliob... | Pembrolizumab Exablate MRgFUS... | 18 Years - | M.D. Anderson Cancer Center | |
| Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer | NCT03107780 | Glioblastoma Gliosarcoma MGMT-Unmethylat... Recurrent Gliob... | Biospecimen Col... Magnetic Resona... Navtemadlin Radiation Thera... | 18 Years - | National Cancer Institute (NCI) | |
| Treatment of Recurrent Glioblastoma With Fractionated Radiotherapy Combined With Cadonilimab | NCT05737368 | Recurrent Gliob... | fractionated ra... cadonilimab | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | NCT01609790 | Giant Cell Glio... Glioblastoma Gliosarcoma Oligodendroglio... Recurrent Brain... Recurrent Gliob... | Bevacizumab Laboratory Biom... Pharmacological... Placebo Adminis... Trebananib | 18 Years - | National Cancer Institute (NCI) | |
| Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) | NCT01906385 | Glioma | Rhenium Liposom... | 18 Years - | Plus Therapeutics | |
| Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer | NCT06058988 | Brain Cancer Glioblastoma Metastatic Canc... Leptomeningeal ... Recurrent Gliob... | Trastuzumab der... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| ASP8374 + Cemiplimab in Recurrent Glioma | NCT04826393 | Glioblastoma Recurrent Gliob... | ASP8374 cemiplimab | 18 Years - | Dana-Farber Cancer Institute | |
| Pilot Trial for Treatment of Recurrent Glioblastoma | NCT05432518 | Glioblastoma Recurrent Disea... Recurrent Gliob... | Afatinib Dasatinib Palbociclib Everolimus Olaparib | 18 Years - | AHS Cancer Control Alberta | |
| Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research | NCT00250887 | Recurrent Gliob... | Gefitnib | 18 Years - | University of Zurich | |
| SCH-900105 in Recurrent Glioblastoma | NCT01189513 | Glioblastoma | SCH 900105 | 18 Years - | M.D. Anderson Cancer Center | |
| HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma | NCT03216499 | Recurrent Gliob... | HIF-2alpha Inhi... Pharmacological... Laboratory Biom... Pharmacogenomic... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma | NCT05236036 | Astrocytoma Glioblastoma Glioblastoma, I... MGMT-Unmethylat... Recurrent Gliob... | Mycophenolate M... Quality-of-Life... Radiation Thera... Temozolomide | 18 Years - | Northwestern University | |
| A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients | NCT02017717 | Recurrent Gliob... | Nivolumab Bevacizumab Ipilimumab | 18 Years - | Bristol-Myers Squibb | |
| Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM | NCT05902169 | Glioblastoma Recurrent Gliob... GBM | SonoCloud-9 (SC... Carboplatin Lomustine Temozolomide | 18 Years - | CarThera | |
| Mathematical Model-Adapted Radiation In Glioblastoma | NCT03557372 | Recurrent Gliob... | Mathematical Mo... | 18 Years - | Dana-Farber Cancer Institute | |
| CARv3-TEAM-E T Cells in Glioblastoma | NCT05660369 | Glioblastoma Malignant Gliom... Recurrent Gliob... Recurrent Gliom... | CARv3-TEAM-E T ... | 18 Years - | Massachusetts General Hospital | |
| Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic Resonance Imaging (MRI) Follow-up in Re-irradiated Recurrent Glioblastoma Patients | NCT01579253 | Glioblastoma Nervous System ... Central Nervous... Astrocytoma Glioma Neoplasms, Neur... Neuroectodermal... Neoplasms by Hi... Neoplasms, Nerv... | 18 Years - 75 Years | Ludwig-Maximilians - University of Munich | ||
| Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma | NCT04717999 | Recurrent Gliob... | NKG2D CAR-T | 20 Years - 70 Years | UWELL Biopharma | |
| Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma | NCT03014804 | Giant Cell Glio... Gliosarcoma Oligodendroglio... Recurrent Gliob... Small Cell Glio... | autologous dend... Laboratory Biom... Nivolumab Quality-of-Life... Questionnaire A... | 18 Years - 75 Years | Jonsson Comprehensive Cancer Center | |
| Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas | NCT02343406 | Glioblastoma | Depatuxizumab m... Temozolomide Lomustine | - 99 Years | AbbVie | |
| Role of Repeat Resection in Recurrent Glioblastoma | NCT04838782 | Recurrent Gliob... Glioblastoma - ... | Repeat Surgical... | 18 Years - | University of Alberta | |
| Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma | NCT02844439 | Glioblastoma Recurrent Gliob... Brain Tumor | Tesevatinib | 18 Years - | Kadmon Corporation, LLC | |
| Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma in Patients Undergoing Craniotomy | NCT05789394 | Recurrent Gliob... | Allogeneic Adip... Biospecimen Col... Craniotomy Magnetic Resona... Ommaya Reservoi... | 18 Years - 65 Years | Mayo Clinic | |
| Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma | NCT02794883 | Malignant Gliom... Recurrent Gliob... | Durvalumab Laboratory Biom... Surgical Proced... Tremelimumab | 18 Years - | Northwestern University | |
| VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM | NCT03149575 | Glioblastoma Mu... Glioblastoma Glioma GBM Brain Cancer | VAL-083, Dianhy... Physician's Cho... Physician's Cho... Physician's Cho... | 18 Years - | Kintara Therapeutics, Inc. | |
| Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas | NCT05737212 | Recurrent High-... Recurrent Gliob... Recurrent Anapl... Recurrent Anapl... | 500mg/kg/3hr fo... 500mg/kg/3hr fo... 500mg/kg/3hr fo... | 19 Years - 80 Years | Dawonmedax Co., Ltd. | |
| RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma | NCT05557292 | Glioblastoma Recurrent Gliob... | RMC-5552 | 18 Years - | University of California, San Francisco | |
| Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma | NCT04729959 | Diffuse Astrocy... Recurrent Gliob... | Atezolizumab Biospecimen Col... Conventional Su... Fractionated St... Magnetic Resona... Tocilizumab | 18 Years - | National Cancer Institute (NCI) | |
| Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib | NCT04004975 | Recurrent Gliob... | Anlotinib | 18 Years - 80 Years | Shandong Cancer Hospital and Institute | |
| Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment | NCT05460507 | Glioma | Retreatment Rhe... | 18 Years - | Plus Therapeutics | |
| A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM | NCT05303467 | Glioblastoma Mu... Recurrent Gliob... | TheraSphere GBM | 18 Years - | Boston Scientific Corporation | |
| Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma | NCT05341947 | Recurrent Gliob... | Activated T cel... | 18 Years - | Cedars-Sinai Medical Center | |
| B7-H3 CAR-T for Recurrent or Refractory Glioblastoma | NCT04077866 | Recurrent Gliob... Refractory Glio... | Temozolomide B7-H3 CAR-T | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Improving Tumor Treating Fields Treatment for Brain Cancer Patients With Skullremodeling Surgery (Neurosurgery) | NCT04223999 | Recurrent Gliob... | Skullremodeling... Control | 18 Years - | University of Aarhus | |
| Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | NCT02101905 | Anaplastic Astr... Anaplastic Epen... Anaplastic Olig... Gliosarcoma Mixed Glioma Recurrent Adult... Recurrent Gliob... | Laboratory Biom... Lapatinib Lapatinib Ditos... Pharmacological... Therapeutic Con... | 18 Years - | National Cancer Institute (NCI) | |
| Ketogenic Diet Adjunctive to Salvage Chemotherapy for Recurrent Glioblastoma:a Pilot Study | NCT02939378 | Glioblastoma Mu... | Ketogenic diet Standard diet | 18 Years - 60 Years | Beijing Tiantan Hospital | |
| A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma | NCT05324501 | Recurrent Gliob... | MTX110 Programmable pu... | 18 Years - | Biodexa Pharmaceuticals | |
| A Panobinostat Presurgery | NCT01115036 | Recurrent Gliob... | panobinostat | 18 Years - | Duke University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
